drugset / Trial / NCT06246071

A Study of TYK-00540 in Adult Patients With Solid Tumors

NCT06246071

Phase 1 Recruiting 156 enrolled TYK Medicines, Inc
NaSequentialOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of TYK-00540, with dose-escalation stage and dose-expansion stage.

Timeline

Start
2024-01-02
Primary completion
2026-12-05
Completion
2026-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject TYK-00540 Unknown Oral

Indications

No indication recorded.